PCVX
Income statement / Annual
Last year (2024), Vaxcyte, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Vaxcyte, Inc.'s net income was -$463.93 M.
See Vaxcyte, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.41 M
|
$1.23 M
|
$1.04 M
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$1.41 M
|
-$1.23 M
|
-$1.04 M
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$476.64 M
|
$332.34 M
|
$169.45 M
|
$78.41 M
|
$73.56 M
|
$45.61 M
|
$30.15 M
|
$12.79 M
|
| General & Administrative Expenses |
$92.90 M
|
$60.70 M
|
$39.81 M
|
$25.26 M
|
$0.00
|
$0.00
|
$5.39 M
|
$5.05 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$92.90 M
|
$60.70 M
|
$39.81 M
|
$25.26 M
|
$14.61 M
|
$7.31 M
|
$5.39 M
|
$5.05 M
|
| Other Expenses |
$0.00
|
$75.00 M
|
$23.00 M
|
$0.00
|
$0.00
|
$0.00
|
$5.18 M
|
$0.00
|
| Operating Expenses |
$569.55 M
|
$468.04 M
|
$232.26 M
|
$103.67 M
|
$88.18 M
|
$52.92 M
|
$35.53 M
|
$17.40 M
|
| Cost And Expenses |
$569.55 M
|
$468.04 M
|
$232.26 M
|
$103.67 M
|
$89.58 M
|
$54.15 M
|
$35.53 M
|
$17.40 M
|
| Interest Income |
$109.99 M
|
$62.91 M
|
$8.36 M
|
$344.00 K
|
$244.00 K
|
$632.00 K
|
$903.00 K
|
$164.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$2.00 K
|
$7.00 K
|
$7.00 K
|
$40.00 K
|
$75.00 K
|
$0.00
|
| Depreciation & Amortization |
$15.85 M
|
$10.17 M
|
$9.45 M
|
$3.46 M
|
$1.41 M
|
$1.23 M
|
$1.04 M
|
$625.00 K
|
| EBITDA |
-$448.08 M |
-$392.10 M |
-$214.03 M |
-$96.61 M |
-$87.81 M |
-$49.00 M |
-$28.37 M |
-$17.21 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$105.62 M
|
$65.78 M
|
$8.77 M
|
$3.59 M
|
$364.00 K
|
$3.88 M
|
$6.05 M
|
$595.00 K
|
| Income Before Tax |
-$463.93 M
|
-$402.27 M
|
-$223.49 M
|
-$100.08 M
|
-$89.22 M
|
-$50.27 M
|
-$29.49 M
|
-$17.24 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$463.93 M
|
-$402.27 M
|
-$223.49 M
|
-$100.08 M
|
-$89.22 M
|
-$50.27 M
|
-$29.49 M
|
-$17.24 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-3.8 |
-4.14 |
-3.44 |
-1.93 |
-2.97 |
-14.1 |
-8.12 |
-4.84 |
| EPS Diluted |
-3.8 |
-4.14 |
-3.44 |
-1.93 |
-2.97 |
-14.1 |
-8.12 |
-4.83 |
| Weighted Average Shares Out |
$122.00 M
|
$97.16 M
|
$64.88 M
|
$51.92 M
|
$29.55 M
|
$3.80 M
|
$3.63 M
|
$3.57 M
|
| Weighted Average Shares Out Diluted |
$122.00 M
|
$97.16 M
|
$64.88 M
|
$51.92 M
|
$29.55 M
|
$3.80 M
|
$3.63 M
|
$3.57 M
|
| Link |
|
|
|
|
|
|
|
|
